A. Martínez-Martí

E. Felip, A. Navarro, A. Martínez-Martí, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer

E. Felip, S. Cedrés, A. Navarro, 2022, Frontiers in Medicine.

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer

R. Herbst, S. Dakhil, D. Camidge, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14).

U. Dafni, D. de Ruysscher, R. Stahel, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient.

E. Felip, A. Vivancos, A. Martínez-Martí, 2019, Pulmonology.

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

N. Viñolas, B. Massuti, V. Calvo, 2022, Journal for ImmunoTherapy of Cancer.

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer.

R. Govindan, R. Kruger, B. Besse, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Single-cell transcriptome conservation in cryopreserved cells and tissues

I. Amit, S. Heath, Diego Jaitin, 2016, Genome Biology.

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.

J. Yokota, D. Pisano, E. Felip, 2017, Clinical cancer research : an official journal of the American Association for Cancer Research.

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition

J. Yokota, D. Pisano, E. Felip, 2017, Clinical Cancer Research.

Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients

E. Felip, S. Cedrés, A. Navarro, 2021, Cancers.

Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer

E. Felip, S. Cedrés, P. Nuciforo, 2020, Molecular oncology.

Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients

E. Felip, S. Cedrés, R. Dienstmann, 2020, Clinical and Translational Oncology.

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

A. Guillaumet-Adkins, E. Felip, S. Cedrés, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation

E. Felip, S. Cedrés, P. Nuciforo, 2018, Journal of the National Cancer Institute.

PI3K Pathway in NSCLC

E. Felip, A. Martínez-Martí, 2012, Front. Oncol..

Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate?

E. Felip, S. Cedrés, P. Martínez, 2014, Lung cancer.

Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)

E. Felip, S. Cedrés, P. Martínez, 2015, PloS one.

Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

E. Felip, S. Cedrés, J. Zugazagoitia, 2016, Lung cancer.

Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort

E. Felip, S. Cedrés, R. Dienstmann, 2021, Scientific Reports.

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

R. Bernards, L. Wessels, E. Felip, 2020, Nature Communications.

Multiple Low Dose (MLD) therapy: an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

R. Bernards, L. Wessels, E. Felip, 2019, bioRxiv.

Epidermal growth factor receptor first generation tyrosine-kinase inhibitors.

E. Felip, A. Navarro, A. Martínez-Martí, 2019, Translational lung cancer research.

Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer

E. Felip, S. Cedrés, P. Nuciforo, 2021, British Journal of Cancer.

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.

I. Wistuba, N. Viñolas, B. Massuti, 2020, The Lancet. Oncology.

Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer

A. Rosenwald, M. Hellmich, E. Smit, 2019, JCO precision oncology.

Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients

E. Felip, S. Cedrés, P. Martínez, 2013, PloS one.

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

I. Wistuba, N. Viñolas, B. Massuti, 2021, Clinical Cancer Research.

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

Keunchil Park, N. Reguart, S. Jabbour, 2021, JAMA oncology.

Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.

N. Reguart, S. Jabbour, M. Reck, 2022, Journal of Clinical Oncology.

PL03.12 Progression Free Survival and Overall Survival in NADIM II Study

J. Bosch-Barrera, M. Provencio, C. Camps, 2022, Journal of Thoracic Oncology.

MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial

J. Bosch-Barrera, M. Provencio, C. Camps, 2022, Journal of Thoracic Oncology.

P2.04-10 Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients

N. Viñolas, B. Massuti, M. Provencio, 2019, Journal of Thoracic Oncology.

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal for ImmunoTherapy of Cancer.

A Placebo‐Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First‐Line Treatment of Patients With Advanced Nonsquamous Non–Small‐Cell Lung Cancer and Systemic Inflammation

G. Giaccone, G. Kennealey, A. Martínez-Martí, 2018, Clinical Lung Cancer.

OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal of Thoracic Oncology.

OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal of Thoracic Oncology.

EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.

M. Tsuboi, U. Dafni, R. Stahel, 2022, Journal of Clinical Oncology.

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

U. Dafni, R. Stahel, M. Mauer, 2022, Annals of Oncology.

PL03.09 IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC

A. Chella, H. Wakelee, C. Zhou, 2022, Journal of Thoracic Oncology.

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

I. Wistuba, N. Viñolas, B. Massuti, 2021, Clinical and translational medicine.

930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091

U. Dafni, R. Stahel, M. Mauer, 2022, Annals of Oncology.

80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study

A. Chella, H. Wakelee, C. Zhou, 2022, Annals of Oncology.

Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC

E. Felip, S. Cedrés, A. Navarro, 2023, Molecular oncology.

KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.

Keunchil Park, N. Reguart, S. Jabbour, 2021 .

Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial

U. Dafni, D. Ruysscher, R. Stahel, 2019, Annals of Oncology.

LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC

R. Herbst, D. Camidge, F. Barlesi, 2021, Annals of Oncology.

Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients

E. Felip, P. Nuciforo, R. Dienstmann, 2023, Cancers.

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

Javier M. Martín-López, J. Bosch-Barrera, N. Reguart, 2023, New England Journal of Medicine.

1278PDMajor pathological response after preoperative chemotherapy as a surrogate marker of survival in early-stage non-small cell lung cancer: cohort of NATCH phase III trial

J. Mate, T. Moran, A. Martínez-Martí, 2017 .

MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry

A. Drilon, H. Wakelee, S. Ou, 2018, Journal of Thoracic Oncology.

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

L. Paz-Ares, J. Zugazagoitia, N. Isambert, 2023, Journal for ImmunoTherapy of Cancer.

Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.

A. Chella, H. Wakelee, E. Felip, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.

E. Felip, A. Martínez-Martí, J. Remon, 2017, Lung cancer.

Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

J. R. Jarabo Sarceda, A. Martínez-Martí, R. Bernabé Caro, 2024, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.